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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMMethods: All patients with severe symptomatic aortic stenosis, CKD (est CrCl<
30mL/min) and BMI< 40kg/m2 undergoing pre-TAVR CTA assessment from 2013-4
at Columbia University Medical Center using the novel protocol were included. Using
a 320-slice volumetric scanner (Aquilion One, Toshiba America Medical Systems),
the protocol included ECG-gated volume scanning of the aortic root followed by
ultrahelical vascular scanning from the aortic arch through femoral arteries, both using
the same 20cc contrast bolus injection. 2 experienced, blinded cardiologists performed
annular and aortic anatomic measurements; agreement was determined using intra-
class correlation coefﬁcient. 2 experienced, blinded radiologists graded image quality
for assessing ileofemoral vascular access on a 4-point scale (1 nondiagnostic; 2
diagnostic but limited; 3 good, mild limitations; 4 excellent); agreement was deter-
mined using weighted kappa.
Results: 19 patients (mean age 83, BMI 24 kg/m2; 53% women) were studied. There
was excellent intra and interobserver agreement for cardiac anatomic measurements
(Table). The average vascular access score was 2.6; both radiologists found diagnostic
quality vascular imaging in 100% of cases with outstanding inter-radiologist agree-
ment (k¼0.91).
Conclusions: This study is the largest of its kind to report the feasibility and
reproducibility of measurements, for a very low contrast dose protocol for
comprehensive pre-TAVR CTA. There was excellent agreement of cardiac mea-
surements and all studies were assessed as diagnostic quality for vascular access
assessment.Table 1. Comparison of Observer Agreement of Measurements Using a Very
Low Contrast Dose Cardiac CTA Protocol
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Background: Preprocedural statin administration might reduce contrast–induced
acute kidney injury (CI–AKI) incidence but current evidence is controversial.
Methods: Randomized controlled trials (RCTs) comparing preprocedural statin
administration before coronary catheterization with standard strategy (hydration alone
or plus Nacetylcysteine) were searched in MEDLINE/PubMed, Embase, Scopus,
Cochrane Library, Web of Science, and ScienceDirect electronic databases. No lan-
guage limitations, ﬁlters or publication date restrictions were applied. A DerSimonian-
Laird random-effects model was used. The endpoint measure, quantiﬁed and reported
as pooled risk ratio (RR) with 95% conﬁdence interval (CI), was CI–AKI incidence.
The inﬂuence of removal of 1 study each time on RR was measured to establish the
impact of individual trials on the pooled effect size. Heterogeneity was graded using
the I2 statistic.
Results: A total of 8 RCTs were included (n¼4984). The incidence of CI-AKI was
3.9% in the statin group (n¼2480) and 7.0% in the control group (n¼2504). In the
pooled analysis patients receiving statins had 46% lower relative risk (RR) of CI-
AKI compared with the control group (RR: 0.54, 95% CI 0.38-0.78, p¼0.001). A
moderate degree of non-signiﬁcant heterogeneity was present (c2¼12.500,
p¼0.099, I2¼ 41.9%, s2¼0.100). The relative weight of each study on the pooled
RR was estimated.Conclusions: Statins administration before coronary angiography or percutaneous
coronary intervention leads to a signiﬁcant risk reduction of CI-AKI development.
Larger double–blind RCTs are requested to conﬁrm this promising results.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ReTCT-256
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Background: Previous studies have suggested that statin pre-treatment prevents
contrast-induced nephropathy (CIN). This meta-analysis aims to assess the role of
statin use in CIN prevention, as well as to determine patient subgroups that will beneﬁt
from statin pre-treatment.
Methods:We searched 843 potentially relevant citations from PubMed, EMBASE,Web
of science and the Cochrane Central Register of Controlled Trials databases for ran-
domized controlled trials (RCT) comparing statin pre-treatment versus placebo for pre-
venting CIN. From this, 9 randomized trials met our inclusion criteria. The primary
endpoint was the incidence of CIN within 2-5 days after contrast administration. Random
effects model was used with Mantel-Haenszel Risk ratio as a summary effect size.
Results: Data analyzed from nine randomized studies with a total of 5,143 patients,
where 2,559 received statins and 2,584 received placebo, showed that statin pre-
treatment was associated with signiﬁcant reduction in risk of CIN (MH-RR¼0.47,
95% CI: 0.34-0.64, Z¼4.49, p< 0.00001). This beneﬁcial effect of statins was also
seen in patients with baseline renal impairment (RR-MH¼0.46, 95% CI: 0.29-0.72,
p¼0.0008) and those who were co-treated with NAC (RR-MH¼0.46, 95% CI: 0.25-
0.83, p¼0.01).Conclusions: Statin pre-treatment leads to signiﬁcant reduction in CIN, and should be
strongly considered in all patients who are planned for diagnostic and interventional
procedures involving contrast-media administration.
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Background: There have been conﬂicting results across the trials that evaluated
prophylactic efﬁcacy of short-term high-dose statin pre-treatment for prevention of
CIN in patients undergoing coronary angiography (CAG). We perform an up-to-date
meta-analysis regarding the efﬁcacy of high-dose statin pre-treatment in preventing
post-procedural incidence of contrast-induced nephropathy (CIN).
Methods: PubMed, EMBASE, BioMed Central, Cochrane Central Register of
Controlled Trials were searched to February 2014. Randomized controlled trials
(RCTs) comparing high-dose statin versus low-dose statin or placebo pre-treatment for
prevention of CIN in patients undergoing CAG were included. The primary endpoint
was the incidence of CIN within 2-5days after CAG. The relative risk (RR) with 95%
CI was the effect measure.
Results: This analysis included 13 RCTs with 5,825 total patients; about half of them
(n¼2,889) were pre-treated with high-dose statin (at least 40mg of atorvastatin) before
CAG, and the remainders (n¼2,936) pretreated with low-dose statin or placebo. In
random-effect model, high-dose statin pre-treatment signiﬁcantly reduced the inci-
dence of CIN (RR 0.45, 95% CI 0.35-0.57, p< 0.001, I2¼8.2%, NNT 16), compared
with low-dose statin or placebo. The beneﬁt of high-dose statin was consistent in both
comparison with low-dose statin (RR 0.47, 95% CI 0.34-0.65, p< 0.001, I2¼28.4%,
NNT 19) or placebo (RR 0.34, 95% CI 0.21-0.58, p< 0.001, I2¼0.0%, NNT 16). In
addition, high-dose statin showed signiﬁcant reduction of CIN across various sub-
groups of chronic kidney disease, acute coronary syndrome, and old age (60years),
regardless of osmolarity of contrast or administration of N-acetylcystein.
Conclusions: High-dose statin pre-treatment signiﬁcantly reduced the incidence of
CIN in patients undergoing CAG. Considering prognostic importance of CIN and
clear beneﬁcial effect of statin in this meta-analysis, high-dose statin pre-treatment
may be more actively employed as an effective prophylactic measure to prevent CIN.nal Insufﬁciency and Contrast Nephropathy B75
